CD274 and colorectal carcinoma: Immunotherapy has also emerged as a promising strategy for CRC treatment, with an increasing number of FDA-approved immunotherapeutic agents being adopted clinically, including immune checkpoint inhibitors targeting programmed cell death ligand 1 (PD-L1) [8].